Fighting leukemia involves a combination of medical treatments tailored to the specific type you have, along with daily habits that protect your body while it’s vulnerable. The four main types of leukemia, acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL), each respond to different treatment strategies, and survival rates vary widely depending on which one you’re facing and your age at diagnosis.
Treatment Depends on the Type
Leukemia isn’t one disease. The “acute” forms (AML and ALL) progress quickly and need aggressive treatment right away. The “chronic” forms (CML and CLL) develop more slowly, and some people with CLL don’t need treatment for years after diagnosis. Your oncologist will determine your treatment plan based on your specific subtype, genetic markers in the cancer cells, your age, and your overall health.
Most treatment plans use some combination of chemotherapy, targeted therapy, immunotherapy, or stem cell transplant. Many people go through treatment in phases: an initial intensive phase to push the cancer into remission, followed by additional rounds to keep it there.
Chemotherapy and Radiation
Chemotherapy remains the backbone of treatment for acute leukemias. For AML, treatment typically starts with an intense induction phase designed to clear leukemia cells from the bone marrow, followed by consolidation therapy to eliminate any remaining cancer. ALL follows a similar pattern but often includes a longer maintenance phase that can stretch over two to three years.
Radiation is less central to leukemia treatment than it is for solid tumors, but it plays a role in certain situations. Total-body irradiation is sometimes used as part of the conditioning process before a stem cell transplant, essentially wiping out the existing bone marrow to make room for healthy donor cells.
Targeted Therapy for CML
Chronic myeloid leukemia was one of the first cancers to get a truly targeted drug. In 2001, the FDA approved a pill that blocks a specific abnormal protein (called BCR-Abl) produced by a genetic defect known as the Philadelphia chromosome. This protein tells leukemia cells to keep growing and dividing. By blocking it, the drug shuts down the signal and lets the cells die normally.
This class of drugs, called tyrosine kinase inhibitors, transformed CML from a near-certain death sentence into a manageable chronic condition. There are now over 50 FDA-approved drugs in this broader class, several of which target CML specifically. Most people with CML take these pills daily, sometimes for the rest of their lives, and many achieve deep, lasting remissions. Some patients who maintain undetectable cancer levels for years can attempt to stop treatment under close medical supervision.
Immunotherapy and CAR-T Cell Therapy
Immunotherapy harnesses your own immune system to recognize and attack leukemia cells. One of the most significant advances is CAR-T cell therapy, which was first approved in 2017 for children with acute lymphoblastic leukemia that had relapsed after other treatments. The treatment works by drawing blood from the patient, genetically engineering the T cells (a type of immune cell) in a lab to recognize leukemia, then infusing those supercharged cells back into the body.
In clinical trials, CAR-T therapy eliminated leukemia in most children with relapsed ALL, and longer-term follow-up shows many of these children survive for years without the cancer returning. Three CAR-T therapies are now approved for different forms of B-cell ALL in both children and adults.
Another immunotherapy approach uses bispecific antibodies, which physically bridge your T cells to leukemia cells so the immune system can destroy them. One such drug is approved for certain forms of ALL and works by connecting T cells directly to a protein on the surface of B-cell leukemia cells, essentially pointing the immune system at its target.
Stem Cell Transplant
A stem cell transplant (sometimes called a bone marrow transplant) offers the possibility of a cure for certain leukemias, particularly acute types that carry a high risk of relapse. The process has several stages, and it’s one of the most physically demanding treatments in cancer care.
First, doctors search for a donor. A fully matched sibling is the ideal source because it carries the lowest risk of complications, but donors can also come from unrelated registries or umbilical cord blood banks. Once a donor is identified, you go through conditioning: a combination of high-dose chemotherapy and sometimes total-body radiation that destroys your existing bone marrow. After conditioning, the donor’s stem cells are infused into your bloodstream, where they migrate to the bone marrow and begin producing healthy blood cells.
Recovery takes weeks to months. During the early period, your immune system is essentially nonexistent, making infection prevention critical. There’s also a risk of graft-versus-host disease, where the donor immune cells attack your healthy tissues. Despite the risks, transplant remains the best chance for long-term survival in many high-risk leukemia cases.
Tracking Progress After Treatment
After initial treatment, doctors use a highly sensitive test to detect tiny amounts of leukemia cells that standard blood tests or biopsies might miss. This testing, called minimal residual disease (MRD) assessment, measures whether leukemia cells remain after treatment, even at levels as low as one cancer cell among thousands of normal ones. MRD results serve as both a prognostic tool and a guide for next steps. If residual disease is detected, your doctor may recommend additional treatment or a transplant. If MRD is negative, it’s a strong signal that the current approach is working.
Survival Rates by Type and Age
Survival statistics vary dramatically by leukemia type and the patient’s age. For AML, the overall five-year survival rate is about 33%, but that number masks huge differences. Children and young adults under 20 have a 71% five-year survival rate. Adults aged 40 to 64 have roughly a 44% rate. For those 75 and older, it drops to around 5%.
CML has one of the more encouraging outlooks thanks to targeted therapy. Many patients now live close to a normal lifespan with ongoing treatment. ALL survival depends heavily on age, with children faring much better than adults. CLL, as a slow-growing leukemia, often has a relatively good prognosis, though it varies based on genetic features of the cancer cells.
Protecting Yourself During Treatment
Leukemia and its treatments severely weaken your immune system by depleting white blood cells, a condition called neutropenia. During these periods, infections that a healthy body would shrug off can become life-threatening. The CDC recommends several precautions: wash your hands frequently, avoid crowded places and contact with sick people, and don’t share food, drinks, or utensils. Shower daily and use unscented lotion to prevent cracked skin, which can let bacteria in. Wear gloves when gardening or cleaning up after pets. Brush your teeth gently with a soft toothbrush, and get a flu shot as soon as it’s available each season.
Food Safety When Your Immune System Is Low
During periods of low white blood cell counts, your doctor may recommend a restricted diet designed to minimize exposure to bacteria in food. The core rules are straightforward: cook all meat, fish, and eggs thoroughly (no runny yolks, no rare steaks, no sushi). Avoid raw fruits and vegetables unless they can be peeled. Skip salad bars, deli counters, and buffets. Stay away from soft cheeses like brie, feta, and blue cheese, as well as unpasteurized dairy products. Don’t eat raw nuts, raw oats, or anything made with raw cookie dough. Avoid yogurt with live cultures and soft-serve ice cream from machines.
These restrictions can feel overwhelming, but they’re temporary. Once your white blood cell counts recover, your medical team will let you know when it’s safe to reintroduce these foods.
Exercise During Treatment
Physical activity during leukemia treatment is not only safe for most patients, it meaningfully reduces fatigue, which is one of the most common and debilitating side effects. The American Cancer Society recommends that cancer survivors build up to 150 to 300 minutes of moderate activity per week (like brisk walking) and include muscle-strengthening exercises at least two days per week.
If you’re exhausted, start with just 10 minutes of light movement a day. You can break activity into short bursts: walk briskly for a few minutes, rest, then go again. Three 10-minute sessions count the same as one 30-minute session. Focus on exercises that use large muscle groups (thighs, chest, back, core), maintain muscle mass and bone strength with resistance bands or light weights, and keep your joints flexible through gentle stretching. Even for people with advanced leukemia, staying active improves quality of life and makes everyday movement easier.